VECTIVBIO HLDG AG's ticker is VECT and the CUSIP is H9060V101. A total of 2 filers reported holding VECTIVBIO HLDG AG in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $21,587 | -1.8% | 2,536,617 | 0.0% | 1.42% | -3.3% |
Q4 2022 | $21,980 | -99.9% | 2,536,617 | 0.0% | 1.47% | +38.3% |
Q3 2022 | $15,220,000 | -0.8% | 2,536,617 | -10.7% | 1.06% | -8.3% |
Q2 2022 | $15,338,000 | +56.7% | 2,840,389 | +36.7% | 1.16% | +54.3% |
Q1 2022 | $9,790,000 | -10.1% | 2,078,485 | -6.2% | 0.75% | +16.2% |
Q4 2021 | $10,884,000 | -36.7% | 2,216,763 | -0.4% | 0.65% | -7.4% |
Q3 2021 | $17,197,000 | -32.6% | 2,226,128 | 0.0% | 0.70% | -19.4% |
Q2 2021 | $25,531,000 | – | 2,226,128 | – | 0.87% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CHI Advisors LLC | 5,255,484 | $44,724,170 | 11.87% |
TCG Crossover Management, LLC | 3,113,600 | $26,496,736 | 5.16% |
CAXTON CORP | 156,651 | $1,345,549 | 3.40% |
VR Adviser, LLC | 1,866,000 | $15,879,660 | 3.10% |
Novo Holdings A/S | 3,610,461 | $30,725,023 | 2.03% |
Cormorant Asset Management, LP | 2,536,617 | $21,587 | 1.42% |
Vivo Capital, LLC | 2,333,300 | $19,856,383 | 1.38% |
Orbimed Advisors | 5,156,561 | $43,882,334 | 0.86% |
Frazier Life Sciences Management, L.P. | 1,352,199 | $11,628,911 | 0.84% |
Bpifrance SA | 2,806,217 | $23,880,907 | 0.61% |